✦ LIBER ✦

Increasing Rate of TAMs and Etravirine Resistance in HIV-1–Infected Adults Between 12 and 24 Months of Treatment

✍ Scribed by Messou, Eugène; Chaix, Marie-Laure; Gabillard, Delphine; Yapo, Vincent; Toni, Thomas-d’Aquin; Minga, Albert; Kouakou, Martial Guillaume; Ouattara, Eric; Rouzioux, Christine; Danel, Christine; Eholie, Serge P.; Anglaret, Xavier

Book ID: 121730124
Publisher: Lippincott Williams and Wilkins
Year: 2013
Tongue: English
Weight: 154 KB
Volume: 64
Category: Article
ISSN: 1077-9450
DOI: 10.1097/QAI.0b013e3182a009e4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PIN58 COST-EFFECTIVENESS OF ETRAVIRINE I

PIN58 COST-EFFECTIVENESS OF ETRAVIRINE IN SWEDEN IN TREATMENT-EXPERIENCED HIV-I-INFECTED ADULTS WITH EVIDENCE OF NNRTI RESISTANCE AND AT LEAST 3 PI MUTATIONS

✍ Moeremans, K; Hjelmgren, J; Martin, SO 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB

Etravirine in treatment-experienced, HIV

Etravirine in treatment-experienced, HIV-1-infected children and adolescents: 48-week safety, efficacy and resistance analysis of the phase II PIANO study

✍ Tudor-Williams, G; Cahn, P; Chokephaibulkit, K; Fourie, J; Karatzios, C; Dincq, 📂 Article 📅 2014 🏛 John Wiley and Sons 🌐 English ⚖ 276 KB

Efficacy and safety of TMC125 (etravirin

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial

✍ José Valdez Madruga; Pedro Cahn; Beatriz Grinsztejn; Richard Haubrich; Jacob Lal 📂 Article 📅 2007 🏛 The Lancet 🌐 English ⚖ 193 KB

Prevalence of etravirine resistance asso

Prevalence of etravirine resistance associated mutations in HIV-1 strains isolated from infected individuals failing efavirenz: Comparison between subtype B and non-B genetic variants

✍ João Pereira-Vaz; Vitor Duque; Branca Pereira; Vanda Mota; Célia Morais; José Sa 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB

## Abstract Etravirine (ETR) is a non‐nucleoside analogue reverse transcriptase inhibitor (NNRTI) with a high genetic barrier to the development of resistance and with potential activity against __Human immunodeficiency virus type 1__ (HIV‐1) strains resistant to first‐generation NNRTIs. The object

Efficacy and safety of TMC125 (etravirin

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial

✍ Adriano Lazzarin; Thomas Campbell; Bonaventura Clotet; Margaret Johnson; Christi 📂 Article 📅 2007 🏛 The Lancet 🌐 English ⚖ 193 KB

Safety and Efficacy of Dolutegravir in T

Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study

✍ Eron, J. J.; Clotet, B.; Durant, J.; Katlama, C.; Kumar, P.; Lazzarin, A.; Poizo 📂 Article 📅 2012 🏛 University of Chicago Press 🌐 English ⚖ 411 KB